Treatment
Cell clinical trials
We’re tracking 5,710 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06587828Recruiting
Looking at immune cells in people with autoimmune disease
This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.
Orange, CaliforniaAges 18 years+ - NCT06588413RecruitingPhase 3
Comparing two doses of olanzapine for nausea after stem cell transplant
This trial tests whether a lower dose of olanzapine (2.5 mg) works as well as the usual dose (5 mg) for preventing nausea and vomiting caused by high-dose melphalan chemotherapy. It is for people receiving their own stem cell transplant.
Augusta, GeorgiaAges 18 years+ - NCT06589609RecruitingPhase 1
FluBHPVE6E7 immunotherapy for HPV16-positive oropharyngeal cancer
This trial tests a new immunotherapy called FluBHPVE6E7 for people with HPV16-positive oropharyngeal cancer that has not spread to distant parts of the body. The treatment is given directly into the tumor to help the immune system fight the cancer.
ViennaAges 18–65 - NCT06590246RecruitingPhase 1/Phase 2
Study of C-CAR031 for advanced GPC3-positive liver cancer
This trial tests a new type of cell therapy called C-CAR031, which is designed to target and attack liver cancer cells that have a protein called GPC3. It is for people with advanced liver cancer who have already tried other treatments and are looking for a new option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06597565RecruitingPhase 2
ACR-368 plus low-dose gemcitabine for advanced head and neck cancer
This study tests a new combination of two drugs, ACR-368 and low-dose gemcitabine, for people with head and neck cancer that has come back or spread. The goal is to see if this treatment can help when immunotherapy or other therapies haven't worked.
Tampa, FloridaAges 18 years+ - NCT06598722RecruitingPhase 2
BCL-2 inhibitor plus HyperCVAD for T-cell lymphoma
This trial tests adding a BCL-2 inhibitor drug to a standard chemotherapy regimen (HyperCVAD) for people newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see if the combination works better than chemotherapy alone.
ShanghaiAges 18–60 - NCT06598527RecruitingPhase 3
Radiation and immunotherapy before surgery for lung cancer
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Guangzhou, GuangdongAges 18–75 - NCT06598839Recruiting
Immune effects of thymosin alpha-1 for stage I lung cancer
This trial tests whether thymosin alpha-1, an immune-boosting medicine, can help people with stage I non-small cell lung cancer after surgery. The goal is to see if it improves the immune system's response and recovery.
Beijing, Beijing MunicipalityAges 18–75 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT06193889RecruitingPhase 2/Phase 3
Car-t cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
Los Angeles, CaliforniaAges 18–75 - NCT07690917Recruiting
New PET scanner study for people with cancer
This trial tests a new PET scanner that may help doctors see where cancer is in your body more clearly. It is for adults with lung, prostate, or head and neck cancer who are already scheduled for a PET-CT scan at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+ - NCT07567235RecruitingPhase 1
CFH Protein Ice Microneedles for Radiation Skin Damage
This study tests a new treatment using ice microneedles to deliver a healing protein (CFH) to prevent skin scarring and fibrosis after radiation therapy for head and neck cancer. The goal is to reduce long-term skin damage from cancer treatment.
Chengdu, SichuanAges 18–75 - NCT07592000RecruitingPhase 1/Phase 2
New Treatment for Type 1 Diabetes With Kidney Disease
This study tests a new experimental medication for people with type 1 diabetes who experience dangerous low blood sugar episodes and have early-stage kidney disease. The trial aims to help improve blood sugar control and reduce these risky episodes.
Chicago, IllinoisAges 18–70 - NCT07620951RecruitingPhase 1
How Your Body Processes an Experimental Cancer Drug
This is an early-stage study testing how a new cancer medication (zorifertinib) moves through and leaves a healthy male body. Researchers use a special radioactive marker to track the drug so they can understand how it works and how safe it is.
Suzhou, JiangsuAges 18–45 - NCT06601296RecruitingPhase 2
Radiation plus immunotherapy for metastatic kidney cancer
This trial tests whether combining radiation therapy with two types of immunotherapy (checkpoint inhibitors and an injectable drug called IMSA101) can help control metastatic kidney cancer that is only growing in a few spots. The goal is to see if this approach can shrink tumors and keep them from growing further.
Dallas, TexasAges 18 years+ - NCT06601309RecruitingPhase 2
Study of treatments before surgery for esophageal cancer
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Fuzhou, FujianAges 18–75 - NCT06602843Recruiting
Chemoimmunotherapy before and after surgery for esophageal cancer
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
HefeiAges 18–75 - NCT06603402RecruitingPhase 2
Low-dose radiation plus immunotherapy for esophageal cancer
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
Chengdu, SichuanAges 18–80 - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06607406Recruiting
Timing of radiation after surgery for head and neck cancer
This study tests whether starting radiation therapy more than 6 weeks (but within 16 weeks) after surgery is safe and effective for people with certain high-risk head and neck cancers. It could help those who had to delay radiation for recovery or other reasons.
Charlotte, North CarolinaAges 18 years+ - NCT06607419RecruitingPhase 2/Phase 3
Blinatumomab for leftover leukemia in children with B-ALL
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
Hefei, AnhuiAges 1 month–18 years - NCT06608355RecruitingPhase 1
Stem cell treatment for early-onset Parkinson's
This trial tests a new stem cell treatment called NouvNeu001 for people with early-onset Parkinson's disease. The goal is to see if it's safe and if it can help improve movement and daily life.
Wuhan, HubeiAges 18–70 - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,710 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.